What Is Leptin? Benefits, Research & Safety
A hormone produced by fat cells that regulates appetite, energy expenditure, and body weight.
UK summary: Endogenous satiety hormone. The recombinant analogue metreleptin (Myalept) is licensed in some jurisdictions for rare leptin-deficiency states; common obesity is leptin-resistant, so adding leptin generally does not help.
Quick Facts
Overview
Leptin — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Endogenous satiety hormone. The recombinant analogue metreleptin (Myalept) is licensed in some jurisdictions for rare leptin-deficiency states; common obesity is leptin-resistant, so adding leptin generally does not help.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Metreleptin (Myalepta) available through specialist centres for lipodystrophy. Strict prescribing guidelines apply.
- EU: EMA approval for generalised lipodystrophy. Requires specialist metabolic centre prescription.
- Notes: Leptin-based therapy is highly targeted to conditions with true leptin deficiency. It is not approved or effective for common obesity. Researchers continue to explore leptin sensitizers and combination approaches, but no products are yet approved for general weight management.
05Approved medical uses
- Congenital leptin deficiency (metreleptin / Myalept — licensed in some jurisdictions; NOT MHRA-licensed in UK; rare-disease indication).
- Generalised lipodystrophy (metreleptin — same status).
06Unapproved / promotional claims
- Leptin injections cause weight loss in common obesity.
- Oral 'leptin support' supplements raise leptin levels.
- Leptin restores appetite control after dieting.
- Self-administered leptin treats obesity at home.
07Common internet claims
- Marketed as 'leptin supplements' / 'leptin support' formulas in wellness retail.
- Sold by some online retailers as research-only injectable.
- Promoted in 'leptin resistance' diet protocols.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Leptin injections cause weight loss in obesity” | C | Yes | High | Effective only in rare leptin-deficient states. Common obesity is leptin-resistant; supplementation does not overcome this. |
| “Leptin supplements work” | E | No | High | Oral leptin is degraded; no evidence-based 'leptin supplement' exists. |
09Safety uncertainty score
Safety profile partly characterised; some signals from observational or preclinical data.
10Known adverse signals
- Metreleptin in licensed indications: injection-site reactions, hypoglycaemia, antibody formation.
- Risk of T-cell lymphoma reported in some patients with acquired generalised lipodystrophy.
- Theoretical immune-modulation risks with chronic exogenous leptin.
11Drug-interaction uncertainty
Some interaction data published; check with a prescriber for your specific medicines.
12Anti-doping status
13UK legal position
Metreleptin (Myalepta) available through specialist centres for lipodystrophy. Strict prescribing guidelines apply.
Read the full UK legal guide → Are peptides legal in the UK?
14EU legal position
EMA approval for generalised lipodystrophy. Requires specialist metabolic centre prescription.
15What this page cannot tell you
- Whether a UK-purchased 'leptin' product contains the protein at the labelled concentration.
- Whether you actually have leptin deficiency — almost certainly not (extremely rare condition).
- Whether your weight regulation problem is leptin-driven (mostly it isn't; common obesity is leptin-resistant).
16Last reviewed
17Citation quality score
18Research gaps
- Leptin agonist / sensitiser drugs are in early research; no licensed UK products.
- Mechanisms of leptin resistance not fully characterised at clinical level.
19Safer alternatives / established care pathways
- Licensed Wegovy (semaglutide) or Mounjaro (tirzepatide) via NHS or GMC-registered prescriber for clinically significant obesity.
- NHS Tier 2 / 3 weight management programmes for structured behaviour change.
- Endocrinology / metabolic-medicine referral for suspected rare conditions.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is leptin therapy appropriate for my situation?
- What licensed UK weight-management options should I consider?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Effective treatment for congenital leptin deficiency (dramatic weight loss)
- 2Approved for metabolic complications of generalised lipodystrophy
- 3Restores menstrual function in leptin-deficient women
- 4Improves insulin sensitivity in lipodystrophy
- 5Reduces triglycerides and hepatic steatosis in lipodystrophy
- 6Research into hypothalamic amenorrhea treatment ongoing
Claim vs Evidence
How popular claims about Leptin stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Leptin injections cause weight loss in obesity” | C | Yes | High | Effective only in rare leptin-deficient states. Common obesity is leptin-resistant; supplementation does not overcome this. |
| “Leptin supplements work” | E | No | High | Oral leptin is degraded; no evidence-based 'leptin supplement' exists. |
Theoretical Dosing & Protocols
| Theoretical Dosage | Lipodystrophy: weight-based dosing (e.g., 0.06 mg/kg/day, adjusted based on response) |
| Frequency | Once or twice daily subcutaneous injection |
| Duration | Chronic treatment for ongoing indications |
| Notes | Metreleptin is only approved for specific conditions with leptin deficiency or resistance (lipodystrophy). It is NOT effective for common obesity due to leptin resistance. Use requires specialist prescription and monitoring. Off-label use for weight loss is not supported by evidence. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (only approved route)
| Half-Life | Stability |
|---|---|
| Approximately 3-4 hours for recombinant leptin | Requires refrigeration; reconstituted solutions should be used within manufacturer specifications |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Injection site reactions
- Headache
- Hypoglycaemia (especially if on insulin)
- Weight loss (intended effect in appropriate patients)
- Fatigue
Rare Risks & Concerns
- Development of anti-leptin antibodies (can neutralise effect)
- T-cell lymphoma (boxed warning—observed in lipodystrophy patients, unclear if drug-related)
- Severe infections
- Autoimmune disorders
Contraindications
- Patients with obesity not related to leptin deficiency
- Known hypersensitivity to metreleptin
- General obesity (due to lack of efficacy and potential risks)
UK & EU Regulatory Context
🇬🇧 United Kingdom
Metreleptin (Myalepta) available through specialist centres for lipodystrophy. Strict prescribing guidelines apply.
🇪🇺 European Union
EMA approval for generalised lipodystrophy. Requires specialist metabolic centre prescription.
Clinical Studies Summary
Leptin Treatment of Congenital Leptin Deficiency
Landmark studies showing dramatic weight loss and metabolic improvement in rare patients with genetic leptin deficiency.
Leptin and Hypothalamic Amenorrhea
Research on leptin replacement in women with exercise-induced or low-weight amenorrhea showing restoration of menstrual function.
The effectiveness of fasting regimens on serum levels of some major weight regulating hormones: a GRADE-assessed systematic review and meta-analysis in randomized controlled trial.
Ethics, consent to participate: Not applicable. Consent for publication: Not applicable.
Relationship Between Leptin and Heart Failure: A Meta-Analysis.
To our knowledge, this systematic review is the first to evaluate the relationship between leptin and HF. Determining the role of leptin in HF will significantly contribute to its diagnosis and treatment.
Circulating leptin levels in thyroid dysfunction: a systematic review and meta-analysis.
Compared to euthyroidism, circulating leptin levels were significantly higher in hypothyroidism, and not significantly altered in hyperthyroidism. Besides, leptin levels in TD may be directly regulated by TSH and T3 levels, independent of BMI.
Correlations between circulating adipokines and hepatocellular carcinoma: a Systematic Review and meta-analysis.
There is a significant association between circulating adipokines and HCC, and the presence of viral hepatitis is an influencing factor. Most adipokines are differentially expressed in HCC patients, and some may serve as biomarkers for early diagnosis or prognostic assessment.
Registered Trials & Regulatory Status
13 of 24 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.
A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults
Status: Recruiting · 4 participants · Regeneron Pharmaceuticals
Conditions: Monogenic Obesity
Hunger Perception and Weight-Related Outcomes Following Use of a Leptin-Supporting Dietary Supplement
Status: Recruiting · 100 participants · Efforia, Inc
Conditions: Hunger, Weight Change
Leptin: A Marker for AML Chemo-Sensitivity
Status: Recruiting · 86 participants · Fujian Medical University Union Hospital
Conditions: AML, Adult
Effect of Triticum Aestivum on Appetite, Ghrelin, Leptin, Adiponectin Hormonal Axis in Patients With Obesity
Status: Unknown · 38 participants · Coordinación de Investigación en Salud, Mexico
Conditions: Obesity, Leptin Deficiency, Ghrelin
Salivary and Serum Leptin Levels in Oral Lichen Planus Patients: A Case-control Study.
Status: Completed · 78 participants · Cairo University
Conditions: Oral Lichen Planus, Leptin Levels
Sequencing of 14 Genes From Leptin Melanocortin Pathway in Severe Obesity in Childhood.
Status: Unknown · 100 participants · Central Hospital, Nancy, France
Conditions: Obesity, Child
Serum Prolidase Activity and the Role of Leptin in Osteomalacia
Status: Unknown · 38 participants · TUĞBA ŞAHBAZ
Conditions: Osteomalacia
Assessment of Serum Leptin in Vitiligo Patients
Status: Unknown · 400 participants · Sohag University
Conditions: Vitiligo
Leptin, Adiponectin, FRAP and Tac in Patients With Early Childhood Caries
Status: Unknown · 40 participants · University of Novi Sad
Conditions: Early Childhood Caries
Omega-3 on Lipid Profile and Serum Leptin Level n Neonates With Intrauterine Growth Restriction
Status: Completed · 70 participants · Tanta University
Conditions: Lipid Profile, Neonates, Intrauterine Growth Restriction
Leptin and Liver Enzymes Responses to Aerobic Training in Hepatitis c Patients
Status: Unknown · 40 participants · Cairo University
Conditions: Hepatitis C
Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy
Status: Completed · 16 participants · Regeneron Pharmaceuticals
Conditions: Generalized Lipodystrophy
Adverse event reports (FDA FAERS)
- asthenia2
- drug ineffective2
- drug ineffective for unapproved indication2
- off label use2
- adhesion1
- anaemia1
- angioedema1
- arthralgia1
- cardio-respiratory arrest1
- dengue fever1
FDA FAERS spontaneous reports. A report is not proof the substance caused the event, and an absence of reports is not evidence of safety.
Source: ClinicalTrials.gov and openFDA. Updated automatically.
Looking for Leptin?
Source research-grade Leptin from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Leptin
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is leptin therapy appropriate for my situation?
- What licensed UK weight-management options should I consider?
UK regulatory & safety context
Related Peptides
Semaglutide
A GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment, representing one of the most significant advances in weight management pharmacotherapy.
Learn moreGLP-1
A naturally occurring gut hormone that regulates glucose metabolism and appetite, serving as the basis for major obesity and diabetes medications.
Learn moreGhrelin
The 'hunger hormone' that stimulates appetite and growth hormone release, with important roles in metabolism and energy balance.
Learn moreAmylin
A pancreatic hormone co-secreted with insulin that regulates glucose and appetite, the basis for the diabetes drug pramlintide.
Learn more